Eisai learns from Biogen’s Aduhelm disaster
Leqembi's accelerated approval sees Eisai upholding its part of the bargain, setting a reasonable price and moving fast with confirmatory data.
Regulatory developments over the Christmas period
The FDA and Biogen come in for fierce Congressional criticism, and a handful of new cancer drugs are approved in Japan.
Gilead goes long-acting in HIV
Sunlenca gets a US green light at the second time of asking, but combination success will be vital to it fulfilling its promise.
An expensive new haemophilia gene therapy hits the US
The approval is good for CSL, and better for Uniqure.
U-turn confirms that the US cut-price oncology model is dead
EQRX tears up plans to challenge US PD-(L)1 players on price, and switches focus to two non-discounted small molecules.
